A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

488

Participants

Timeline

Start Date

March 19, 2024

Primary Completion Date

August 20, 2025

Study Completion Date

August 20, 2025

Conditions
Moderate to Severe Glabellar Lines
Interventions
BIOLOGICAL

Rcombinant botulinum neurotoxin type A for injection (YY001)

Five sites will be injected at 0.05 mL each, 2 sites in corrugator muscle of each side and 1 site in the procerus muscle, for a total dose of 20U.

Trial Locations (16)

Unknown

Guangdong Second People's Hospital, Guangzhou

Nanfang Hospital, Southern Medical University, Guangzhou

The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

The Third Xiangya Hospital of Central South University, Changsha

The Second Affiliated Hospital Of Xi'an Jiaotong University, Xian

West China School of Medicine/West China Hospital of Sichuan University, Chengdu

Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine, Hangzhou

Zhejiang Provincial People's Hospital, Hangzhou

Beijing Tsinghua Changgung Hospital, Beijing

Peking Union Medical College Hospital , Chinese Academy of Medical Sciences, Beijing

Peking University First Hospital, Beijing

Peking University Third Hospital, Beijing

Plastic Surgery Hospital, Chinese Academy of Medical Science, Beijing

The First Affiliated Hospital of Chongqing Medical University, Hongqing

Tianjin Medical University General Hospital, Tianjin

All Listed Sponsors
lead

Chongqing Claruvis Pharmaceutical Co., Ltd.

INDUSTRY

NCT06583486 - A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines | Biotech Hunter | Biotech Hunter